Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...

Uy Ear has given his Buy rating due to a combination of factors that highlight Alkermes’ strong performance and future potential. The company’s third-quarter 2024 results were robust ...

Growth investors, on the other hand, are more concerned with a company's financial strength ... the Sep 2011 merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), the ...

Dublin, Ireland-based Alkermes plc was formed by the Sep 2011 merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies ... global biopharmaceutical company that utilizes proprietary ...

The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness relating to its external revenue streams. Alkermes is a biopharmaceutical ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs ...

Alkermes plc (NASDAQ:ALKS – Get Free Report) saw a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 15,820,000 shares, a ...

The company's EPS beat by $0.02 in the last quarter, leading to a 5.77% increase in the share price on the following day. Shares of Alkermes were trading at $28.1 as of October 22. Over the last ...

In a report released yesterday, Joseph Thome from TD Cowen maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report). The ...

Dublin, Ireland-based Alkermes plc was formed by the Sep 2011 merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies ... global biopharmaceutical company that utilizes proprietary ...

For growth investors, a company's financial strength ... plc was formed by the Sep 2011 merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), the drug delivery unit of ...